VENXXIVA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VENXXIVA (VENXXIVA).

How it works

Venetoclax is a selective inhibitor of B-cell lymphoma-2 (BCL-2), an anti-apoptotic protein overexpressed in various hematologic malignancies. By binding to BCL-2, venetoclax displaces pro-apoptotic proteins like BIM, leading to mitochondrial outer membrane permeabilization and activation of caspases, resulting in apoptosis.

What the body does with it

Metabolism	Primarily metabolized by CYP3A4. Minor contributions from CYP2C8, CYP2C9, CYP2C19, UGT1A1, and UGT1A3.
Excretion	Primarily hepatic metabolism with biliary excretion of metabolites; renal excretion of unchanged drug accounts for <5%. Fecal elimination accounts for ~60% of total clearance.
Half-life	Terminal elimination half-life is 12 hours (range 10-14 hours); permits twice-daily dosing with steady-state achieved within 2 days.
Protein binding	98% bound to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.5 L/kg (approximately 35 L in a 70 kg adult), indicating moderate tissue distribution.
Bioavailability	Oral bioavailability is 75% (range 70-80%) with food decreasing absorption by 10%.
Onset of Action	Oral: 30-60 minutes to detectable serum concentrations; peak effect at 2-4 hours post-dose.
Duration of Action	12 hours; supports twice-daily dosing with sustained therapeutic levels.

Classification & Brands

Dosing & administration

800 mg orally twice daily with food.

Dosage form	TABLET, DELAYED RELEASE
Renal impairment	No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, not recommended due to lack of safety data.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce to 400 mg twice daily. Child-Pugh C: contraindicated.
Pediatric use	Not established; safety and efficacy in pediatric patients have not been studied.
Geriatric use	No specific dose adjustment; use with caution due to age-related renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VENXXIVA (VENXXIVA).

Breastfeeding	Contraindicated. M/P ratio not established. Excreted in human milk; potential for severe adverse reactions in nursing infants.
Teratogenic Risk	First trimester: Risk of major malformations (neural tube defects, cardiac anomalies) increased (FDA Category X). Second/third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects). Avoid in pregnancy.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Tumor lysis syndrome (TLS): Risk is highest at initiation and during dose ramp-up. Prophylaxis and monitoring are required; venetoclax is contraindicated for use in patients with CLL/SLL who require dose adjustment for certain drug interactions because of the risk of TLS.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Concomitant use with strong CYP3A inhibitors at initiation and during ramp-up phase (for CLL/SLL indication)","Concomitant use with strong CYP3A inducers (for CLL/SLL indication)","Known hypersensitivity to venetoclax or any excipients"]

Clinical Precautions

Precautions

["Tumor lysis syndrome: risk increased with high tumor burden; ensure prophylaxis and monitoring.","Neutropenia: monitor blood counts and manage with dose interruption or growth factors.","Infections: increased risk of serious infections.","Immunization: avoid live vaccines.","Effects on fertility: may impair fertility."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

VENXXIVA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VENXXIVA (VENXXIVA).

How it works

What the body does with it

Metabolism	Primarily metabolized by CYP3A4. Minor contributions from CYP2C8, CYP2C9, CYP2C19, UGT1A1, and UGT1A3.
Excretion	Primarily hepatic metabolism with biliary excretion of metabolites; renal excretion of unchanged drug accounts for <5%. Fecal elimination accounts for ~60% of total clearance.
Half-life	Terminal elimination half-life is 12 hours (range 10-14 hours); permits twice-daily dosing with steady-state achieved within 2 days.
Protein binding	98% bound to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.5 L/kg (approximately 35 L in a 70 kg adult), indicating moderate tissue distribution.
Bioavailability	Oral bioavailability is 75% (range 70-80%) with food decreasing absorption by 10%.
Onset of Action	Oral: 30-60 minutes to detectable serum concentrations; peak effect at 2-4 hours post-dose.
Duration of Action	12 hours; supports twice-daily dosing with sustained therapeutic levels.

Classification & Brands

Dosing & administration

800 mg orally twice daily with food.

Dosage form	TABLET, DELAYED RELEASE
Renal impairment	No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, not recommended due to lack of safety data.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce to 400 mg twice daily. Child-Pugh C: contraindicated.
Pediatric use	Not established; safety and efficacy in pediatric patients have not been studied.
Geriatric use	No specific dose adjustment; use with caution due to age-related renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VENXXIVA (VENXXIVA).

Breastfeeding	Contraindicated. M/P ratio not established. Excreted in human milk; potential for severe adverse reactions in nursing infants.
Teratogenic Risk	First trimester: Risk of major malformations (neural tube defects, cardiac anomalies) increased (FDA Category X). Second/third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects). Avoid in pregnancy.
Fetal Monitoring